SJS/TEN following therapy with pembrolizumab and enfortumab vedotin in a patient with urothelial carcinoma
Open Access
- 18 February 2026
- journal article
- Published by Elsevier in JAAD Case Reports
- Vol. 71, 25-27
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Characterization of adverse cutaneous effects in the setting of enfortumab vedotin for metastatic urothelial carcinoma: A retrospective reviewJournal of the American Academy of Dermatology, 2024
- Enfortumab vedotin toxic epidermal necrolysis–like blistering dermatosis: A case series and review of the literatureJAAD Case Reports, 2023
- Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab VedotinThe Oncologist, 2022
- Severe cutaneous drug toxicity following enfortumab vedotin treatment for metastatic urothelial carcinomaJAAD Case Reports, 2022
- Postmarketing Cases of Enfortumab Vedotin–Associated Skin Reactions Reported as Stevens-Johnson Syndrome or Toxic Epidermal NecrolysisJAMA Dermatology, 2021